Prevalence of endocrine disorders among children exposed to Lavender Essential Oil and Tea Tree Essential Oils.
Aromatherapy
Endocrine disruption
Lavender essential oil
Precocious puberty
Prepubertal gynecomastia
Tea tree essential oil
Journal
International journal of pediatrics & adolescent medicine
ISSN: 2352-6467
Titre abrégé: Int J Pediatr Adolesc Med
Pays: Netherlands
ID NLM: 101670718
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
19
05
2021
revised:
15
07
2021
accepted:
03
10
2021
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
ppublish
Résumé
Lavender essential oil and tea tree essential oil have become popular ingredients in personal care and household products in recent decades. Questions regarding the safety of these oils in pediatric populations have been raised, proposing a link between these essential oils and endocrine disruption in children, specifically prepubertal gynecomastia. To date, no epidemiological studies have been conducted to evaluate this proposed link. This is a cross sectional study conducted among parents of children in the United States to identify the prevalence of endocrine disruption in children aged 2-15 years old. This study also evaluates the potential for a relationship between the exposure of lavender essential oil and tea tree essential oil products and endocrine disrupting outcomes. In 556 children with a mean age of 6.33 (SD = 3.92), prevalence of endocrine disruption was .016 (SD = 0.13). No cases of prepubertal gynecomastia were identified in either group, and prevalence of precocious puberty, delayed puberty, growth hormone deficiency, and hypothyroidism were all consistent with population norms. Total risk of endocrine disorders among those exposed (0.0194) did not differ from the risk of those unexposed (0.0069). The risk ratio was 2.796 (95% CI: 0.352, 22.163, Children who were regularly exposed to lavender or tea tree essential oils experienced the same risk of endocrine disorders as those who were not exposed.
Sections du résumé
Background
UNASSIGNED
Lavender essential oil and tea tree essential oil have become popular ingredients in personal care and household products in recent decades. Questions regarding the safety of these oils in pediatric populations have been raised, proposing a link between these essential oils and endocrine disruption in children, specifically prepubertal gynecomastia. To date, no epidemiological studies have been conducted to evaluate this proposed link.
Methods
UNASSIGNED
This is a cross sectional study conducted among parents of children in the United States to identify the prevalence of endocrine disruption in children aged 2-15 years old. This study also evaluates the potential for a relationship between the exposure of lavender essential oil and tea tree essential oil products and endocrine disrupting outcomes.
Results
UNASSIGNED
In 556 children with a mean age of 6.33 (SD = 3.92), prevalence of endocrine disruption was .016 (SD = 0.13). No cases of prepubertal gynecomastia were identified in either group, and prevalence of precocious puberty, delayed puberty, growth hormone deficiency, and hypothyroidism were all consistent with population norms. Total risk of endocrine disorders among those exposed (0.0194) did not differ from the risk of those unexposed (0.0069). The risk ratio was 2.796 (95% CI: 0.352, 22.163,
Conclusion
UNASSIGNED
Children who were regularly exposed to lavender or tea tree essential oils experienced the same risk of endocrine disorders as those who were not exposed.
Identifiants
pubmed: 35663791
doi: 10.1016/j.ijpam.2021.10.001
pii: S2352-6467(21)00085-5
pmc: PMC9152575
doi:
Types de publication
Journal Article
Langues
eng
Pagination
117-124Informations de copyright
© 2021 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest associated with this publication, and there has been no significant financial support for this work that could have influenced its outcome.
Références
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5393-5405
pubmed: 31393563
BMC Complement Altern Med. 2016 Nov 9;16(1):450
pubmed: 27829428
J Med Food. 2015 Feb;18(2):241-9
pubmed: 25105335
J Expo Sci Environ Epidemiol. 2015 May;25(3):271-7
pubmed: 24849798
Curr Opin Endocrinol Diabetes Obes. 2012 Feb;19(1):47-52
pubmed: 22157400
Arch Dis Child. 2000 Sep;83(3):207-10
pubmed: 10952634
N Engl J Med. 2007 Feb 1;356(5):479-85
pubmed: 17267908
Expert Rev Endocrinol Metab. 2011 Sep;6(5):723-730
pubmed: 30780874
Eur J Pediatr. 2020 Jun;179(6):985-992
pubmed: 32030454
Clin Microbiol Rev. 2006 Jan;19(1):50-62
pubmed: 16418522
BMC Infect Dis. 2006 Nov 03;6:158
pubmed: 17083732
J Clin Endocrinol Metab. 2020 Sep 1;105(9):
pubmed: 32579676
Complement Ther Clin Pract. 2020 Aug;40:101182
pubmed: 32891272
C R Biol. 2017 Sep - Oct;340(9-10):403-405
pubmed: 29126512
Psychoneuroendocrinology. 2008 Apr;33(3):328-39
pubmed: 18178322
J Drugs Dermatol. 2012 Mar;11(3):349-54
pubmed: 22395586
Phytother Res. 2002 Jun;16(4):301-8
pubmed: 12112282
Recent Pat Endocr Metab Immune Drug Discov. 2017;10(2):127-137
pubmed: 28260521
Pediatr Rev. 2010 May;31(5):189-95
pubmed: 20435710
Pediatr Rev. 2001 Sep;22(9):309-15
pubmed: 11533380
Mayo Clin Proc. 2009 Nov;84(11):1010-5
pubmed: 19880691
Curr Opin Pediatr. 2008 Aug;20(4):465-70
pubmed: 18622206
Eur Arch Paediatr Dent. 2020 Feb;21(1):61-66
pubmed: 31111439
J Obstet Gynecol Neonatal Nurs. 2007 May-Jun;36(3):263-74
pubmed: 17489932
JAMA. 2011 Mar 16;305(11):1134-5
pubmed: 21406653
J Clin Endocrinol Metab. 2020 Jul 1;105(7):
pubmed: 32379885
Complement Ther Med. 2020 Mar;49:102288
pubmed: 32147050
Australas J Dermatol. 2018 May;59(2):e99-e105
pubmed: 28266704
J Pediatr Endocrinol Metab. 2016 Jan;29(1):103-7
pubmed: 26353172
J Adolesc Health. 2007 Aug;41(2):126-31
pubmed: 17659215
Medicine (Baltimore). 2019 Oct;98(40):e17374
pubmed: 31577740
Clin Endocrinol (Oxf). 2004 Jul;61(1):55-60
pubmed: 15212645
Int J Pediatr Otorhinolaryngol. 2013 Sep;77(9):1579-81
pubmed: 23932834
Curr Opin Pediatr. 2008 Aug;20(4):375-82
pubmed: 18622190
Drugs R D. 2014 Dec;14(4):265-72
pubmed: 25319228
Int J Toxicol. 2013 Mar-Apr;32(2):123-9
pubmed: 23358464
J Pediatr Nurs. 2019 Mar - Apr;45:e64-e72
pubmed: 30711327
BMC Dermatol. 2010 Aug 20;10:6
pubmed: 20727129
Curr Opin Pediatr. 2013 Apr;25(2):247-54
pubmed: 23429708
Ann Pediatr Endocrinol Metab. 2014 Sep;19(3):159-63
pubmed: 25346921
Lancet Diabetes Endocrinol. 2016 Mar;4(3):265-274
pubmed: 26852255
Ther Adv Med Oncol. 2018 Apr 02;10:1758835918766189
pubmed: 29636827
Evid Based Complement Alternat Med. 2010 Mar;7(1):11-28
pubmed: 18955327
Expert Opin Pharmacother. 2018 Jul;19(10):1057-1070
pubmed: 30056792
Arch Pediatr Adolesc Med. 2012 Jun 1;166(6):E1-7
pubmed: 22664748
Eur J Pediatr. 2021 Mar;180(3):977-982
pubmed: 32975593
Dermatitis. 2011 Nov-Dec;22(6):344-7
pubmed: 22653008
Best Pract Res Clin Endocrinol Metab. 2019 Jun;33(3):101300
pubmed: 31401055
Clin Pediatr (Phila). 2015 May;54(5):414-24
pubmed: 25022947